Approaches to Primary Prevention of Cardiovascular Diseases in Dyslipidemia
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
Timely and active treatment of patients with risk factors and clinically expressed diseases of the cardiovascular system is one of the priorities of modern medicine. Correction of lipid metabolism disorders has become one of the strategic directions. Dyslipidemia is one of the key factors in the progression of atherosclerosis. Currently, the possibilities of using therapy, which is aimed at lowering lipid levels, have significantly expanded. It is recommended not only to patients with clinical manifestations of atherosclerosis, but also to patients without them, with a high risk of its development. Recently, more and more scientists have been attracting by plant stanols.
The objective: study was to assess the effect of Cholestol® on lipid metabolism in patients with dyslipidemia with a moderate risk of developing cardiovascular disease (CVD).
Materials and methods. 43 patients with stage 1–2 stage of the arterial hypertension with a moderate risk of CVD were examined (total risk according to the SCORE scale (Systematic Coronary Risk Evaluation) ≥1 and <5%)), who had a standard general clinical examination with an assessment of risk factors for development CVD and indicators of lipid and carbohydrate profiles, and also body composition. Patients were divided into 2 groups: group 1 – comparison group, n=15 and group 2 – main, n=28. All patients were advised to adhere diet and physical activity according to European recommendations. Additionally, patients of group 2 were prescribed Nutraceutical Cholestol®, 1 tablet of which contains 400 mg of phytosterol (80% beta-sitosterol, campesterol and stigmasterol), 40 mg of L-methionine, and 5 mg of policosanol 1 tablet 3 times a day with meals. Repeated examination was carried out after 3 months.
Results. Patients of the main group were significantly more likely to have burdened heredity in CVD; they had a significantly higher level of blood pressure, p = 0.0001. After a 3-month observation by anthropometric indicators, there were no significant changes in the comparison group, except for the body mass index (BMI), which may be due to compliance with dietary and physical activity recommendations in patients of this group. Patients who took Cholestol® additionally showed a significant decrease in BMI and visceral fat by 13,5% (p<0.05). The positive effect of Cholestol® on lipid metabolism was important: a significant decrease in the level of cholesterol (16%; p<0,05), LDL-C (28,5%; p<0,05) and TG (19,0%, p <0 , 05). From the side of indicators of the functional state of the liver, there were no negative changes, which is evidence that the use of Cholestol® is safe.
Conclusions. It is advisable to prescribe Cholestol®, the components of which have a proven lipid-lowering effect, for patients with a low and moderate risk of cardiovascular disease. Its use is not accompanied by any side effects during the treatment.##plugins.themes.bootstrap3.article.details##
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
References
Allender S, Scarborough P, Peto V, Rayner M, Leal J, Luengo-Fernandez R, Gray A. European cardiovascular disease statistics, 2008 ed. European Heart Network 2008.
Cardiovascular disease in Europe 2014: epidemiological update / M. Nicholas, N. Townsend., P. Scarborough, M. Rayner // Eur. Heart J. – 2014. – Vol. 35 (42). – P. 2929. doi: 10.1093/eurheartj/ehu378
Townsend N, Nichols M, Scarborough P, Rayner M. Cardiovascular disease in Europe–epidemiological update 2015. Eur Heart J 2015;36:26962705.
Demographic and epidemiologic drivers of global cardiovascular mortality / G.A. Roth, M.H. Forouzanfar, A.E. Moran, et al. // N. Engl. J. Med. – 2015. – Vol. 372. – P. 1333–1341.
ESC/EAS Guidelines for the management of dyslipidaemias. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Z, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WMM, Vlachopoulos C, Wood DA, Zamorano JL, Cooney MT; ESC Scientific Document Group. // Eur Heart J 2016;37:29993058.
Профілактика серцево-судинних захворювань. Адаптована клінічна настанова, заснована на доказах / Mіністерствo охорони здоров’я України, Aсоціація кардіологів України, Українська Aсоціація сімейної медицини.2016. http://mtd.dec.gov.ua/images/dodatki/2016_564_PSSZ/2016_564_AKN_ PSSZ
Cooney MT, Dudina AL, Graham IM. Value and limitations of existing scores for the assessment of cardiovascular risk. A review for clinicians. J Am Coll Cardiol 2009;54:1209–1227.
Cooney MT, Dudina A, d’Agostino R, Graham IM. Cardiovascular risk estimation systems in primary prevention. Do they differ? Do they make a difference? Can we see the future? Circulation 2010;122:300–310.
Conroy R, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, De Bacquer D, Ducimetie`re P, Jousilahti P, Keil U, Njølstad I, Oganov RG, Thomsen T, Tunstall-Pedoe H, Tverdal A, Wedel H, Whincup P, Wilhelmsen L, Graham I. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24:987–1003.
D’Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008;117:743–753.
Board J.B.S. Joint British Societies’ consensus recommendations for the prevention of cardiovascular disease (JBS3) / J.B.S. Board // Heart. – 2014. – Vol. 100 (Suppl 2). – P.ii1–ii67.
ESC Guidelines for the diagnosis and management of chronic coronary syndromes: The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC) Juhani Knuuti, William Wijns, Antti Saraste, Davide Capodanno, Emanuele Barbato, Christian Funck-Brentano, Eva Prescott, Robert F Storey, Christi Deaton, Thomas Cuisset, Stefan Agewall, Kenneth Dickstein, Thor Edvardsen, Javier Escaned, Bernard J Gersh, Pavel Svitil, Martine Gilard, David Hasdai, Robert Hatala, Felix Mahfoud, Josep Masip, Claudio Muneretto, Marco Valgimigli, Stephan Achenbach, Jeroen J Bax, ESC Scientific Document Group, // European Heart Journal, ehz425, https://doi.org/10.1093/eurheartj/ehz425.
Dalen JE, Devries S. Diets to prevent coronary heart disease 1957-2013: what have we learned? Am J Med 2014;127:364369.
Eckel RH, Jakicic JM, Ard JD, de Jesus JM, Houston Miller N, Hubbard VS, Lee IM, Lichtenstein AH, Loria CM, Millen BE, Nonas CA, Sacks FM, Smith SC Jr, Svetkey LP, Wadden TA, Yanovski SZ, Kendall KA, Morgan LC, Trisolini MG, Velasco G, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Smith SC Jr, Tomaselli GF; American College of Cardiology /American Heart Association Task Force on Practice Guidelines. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;S76 S99.
Mente A, de Koning L, Shannon HS, Anand SS. A systematic review of the evidence supporting a causal link between dietary factors and coronary heart disease. Arch Intern Med 2009;169:659669.
Chowdhury R, Warnakula S, Kunutsor S, Crowe F, Ward HA, Johnson L, Franco OH, Butterworth AS, Forouhi NG, Thompson SG, Khaw KT, Mozaffarian D, Danesh J, Di Angelantonio E. Association of dietary, circulating, and supplement fatty acids with coronary risk: a systematic review and metaanalysis. Ann Intern Med 2014;160:398-406.
Sirtori CR, Galli C, Anderson JW, Arnoldi A. Nutritional and nutraceutical approaches to dyslipidemia and atherosclerosis prevention: focus on dietary proteins. Atherosclerosis 2009;203:8–17.
Ashley Reaver, Susan Hewlings, Kenneth Westerman, Gil Blander, Thorsten Schmeller, Marianne Heer and Dietrich Rein, A Randomized, Placebo-Controlled, Double-Blind Crossover Study to Assess a Unique Phytosterol Ester Formulation in Lowering LDL Cholesterol Utilizing a Novel Virtual Tracking Tool // Nutrients 2019, 11, 210 рр. 1-13; Nutrients 2019, 11, 2108; doi:10.3390/nu11092108 Received: 18 July 2019; Accepted: 26 August 2019;
Gylling H., Simonen P. Phytosterols, Phytostanols, and Lipoprotein Metabolism // Nutrients, 2015. – Vol. 7. – Р. 7965–7977.
Trautwein E.A., Vermeer M., Hiemstra H., Ras R. LDL-Cholesterol Lowering of Plant Sterols and Stanols-Which Factors Influence Their Effcacy? Nutrients 2018, 10, 1262.
Jones P.J.H., Shamloo M., MacKay D.S., Rideout T.C., Myrie S.B., Plat J., Roullet J.B., Baer D.J., Calkins K.L., Davis H.R. et al. Progress and perspectives in plant sterol and plant stanol research. Nutrition reviews 2018, 76, 725–746.
Gylling H., Plat J., Turley S., Ginsberg H.N., Ellegård L., Jessup W., Silbernagel G. Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease. Atherosclerosis 2014, 232, 346–360. [CrossRef] [PubMed]
Abumweis SS, Barake R, Jones PJ. Plant sterols/stanols as cholesterol lowering agents: a meta-analysis of randomized controlled trials. Food Nutr Res 2008;52: doi:10.3402/fnr.v52io.1811.
Sanchez-Lopez J, Fernandez-Travieso JC, Illnait-Ferrer J, Fernandez-Dorta L, Mendoza-Castano S, Mas-Ferreiro R, Mesa-Angarica M, Reyes-Suarez P. Effects of policosanol in the functional recovery of non-cardioembolic ischemic stroke hypertensive patients // Rev Neurol. 2018 Nov 1;67(9):331-338.
Kevin C Maki, Andrea L Lawless, Matthew S Reeves, Mary R Dicklin, Belinda H Jenks, ED Shneyvas, James R Brooks Lipid-altering effects of a dietary supplement tablet containing free plant sterols and stanols in men and women with primary hypercholesterolaemia: a randomized, placebo-controlled crossover trial //Int J Food Sci Nutr. 2012 Jun; 63(4): 476–482. doi: 10.3109/09637486.2011.636345
Jerad H Dumolt, Todd C Rideout The Lipid-Lowering Effects and Associated Mechanisms of Dietary Phytosterol Supplementation // Curr Pharm Des. 2017; 23(34): 5077–5085. doi: 10.2174/1381612823666170725142337
Carlos Eduardo Cabral, Márcia Regina Simas Torres Klein Phytosterols in the Treatment of Hypercholesterolemia and Prevention of Cardiovascular Diseases //Arq Bras Cardiol. 2017 Nov; 109(5): 475–482. doi: 10.5935/abc.20170158
Reiner Z, Tedeschi-Reiner E, Romic Z. Effects of rice policosanol on serum lipoproteins, homocysteine, fibrinogen and C-reactive protein in hypercholesterolaemic patients. ClinDrug Investig 2005;25:701–707.
